Investment at two sites includes expansion of R&D capabilities and will create 500 new jobs.

Mylan will invest up to $100 million a year over the next five years into expanding operations at its Galway and Dublin sites in Ireland, including enlarging R&D and manufacturing capacity within its respiratory, injectables, and oral solids franchises. Over 500 new jobs will be created, adding to the 700 employees Mylan already has in Ireland, where its Gerard Laboratories and Bioniche Pharma operations are based.

The planned expansion of will be supported through financial incentives provided by the Irish government’s foreign investment agency IDA. “This investment in Mylan’s Irish operations and the growth of our capabilities in the country demonstrate our continued commitment to and confidence in our respiratory franchise and injectable platform, both of which are among Mylan’s many long-term growth drivers,” comments CEO Heather Bresch. “Ireland has also proven to be a valuable location for Mylan, providing the company with access to a skilled and highly educated workforce.” 

Previous articleAbbott’s Parkinson Therapy Benefits On and Off Times in Phase III Trial
Next articlePlexpress to Raise up to $2.3M to Commercialize Multiplex Gene-Expression Analysis Platform